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adOBJECTIVES The aim of this study was to evaluate the cost-effectiveness of drug-coated balloon (DCB) angioplasty
versus standard percutaneous transluminal angioplasty (PTA).
BACKGROUND Recent trials have reported lower rates of target lesion revascularization with DCB angioplasty versus
standard PTA. However, the cost-effectiveness of DCB angioplasty is unknown.
METHODS A prospective economic study was performed alongside the IN.PACT SFA II (IN.PACT Admiral Drug-Coated
Balloon vs. Standard Balloon Angioplasty for the Treatment of Superﬁcial Femoral Artery [SFA] and Proximal Popliteal
Artery [PPA]) trial, which randomized 181 patients with femoropopliteal disease to the IN.PACT DCB versus standard PTA.
Resource use data were collected over 2-year follow-up, and costs were assigned using resource-based accounting and
billing data. Health utilities were assessed using the EuroQol 5-dimensions questionnaire. Cost-effectiveness was
assessed as cost per quality-adjusted life-year (QALY) gained using a decision-analytic model on the basis of empirical
data from the trial assuming identical long-term mortality.
RESULTS Initial costs were $1,129 per patient higher with DCB angioplasty than standard PTA, driven by higher costs for
the DCB itself. Between discharge and 24 months, target limb–related costs were $1,212 per patient lower with DCB
angioplasty such that discounted 2-year costs were similar for the 2 groups ($11,277 vs. $11,359, p ¼ 0.97), whereas
QALYs tended to be greater among patients treated with DCBs (1.53  0.44 vs. 1.47  0.42, p ¼ 0.40). The probability
that DCB angioplasty is cost-effective compared with standard PTA was 70% using a threshold of $50,000 per QALY
gained and 79% at a threshold of $150,000 per QALY gained.
CONCLUSIONS For patients with femoropopliteal disease, DCB angioplasty is associated with better 2-year outcomes
and similar target limb–related costs compared with standard PTA. Formal cost-effectiveness analysis on the basis of
these results suggests that use of the DCB angioplasty is likely to be economically attractive. (J Am Coll Cardiol Intv
2016;9:2343–52) © 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
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2344L ower extremity peripheral arterydisease (PAD) is both common andcostly, affecting more than 8 million
patients in the United States alone at an
annual cost in excess of $21 billion (1–3). In
recent years, endovascular intervention has
become the dominant mode of revasculariza-
tion for patients with symptomatic femoro-
popliteal disease (4), but these procedures
are limited by relatively high rates of reste-
nosis (particularly after percutaneous trans-luminal angioplasty [PTA] alone), leading to costly
repeat procedures (5). Although bare-metal and
drug-eluting stents improve patency compared with
PTA alone, long-term outcomes may be compromisedSEE PAGE 2353by complications such as stent fracture and in-stent
restenosis (6,7).
More recently, paclitaxel-coated balloons have
been shown to reduce rates of restenosis and repeat
revascularization for patients undergoing femo-
ropopliteal intervention without the need for stent
implantation (8–10), leading to U.S. Food and Drug
Administration approval of 2 such devices. Because
drug-coated balloons (DCBs) are signiﬁcantly more
expensive than standard PTA balloons, and given the
large number of patients who may be candidates for
such treatment, it is important to understand the
impact of DCB technology on the costs and cost-
effectiveness of revascularization for symptomatic
PAD. Although several studies have suggested that
DCB angioplasty may be economically attractive
(11,12), these studies were based predominantly on
short-term mechanistic (rather than clinical) out-
comes from early DCB studies. Because the associa-
tion between mechanistic outcomes and clinical and
economic outcomes is not clearly established, ques-
tions remain about the validity of these studies and
their conclusions. To address these gaps in knowl-
edge, we performed a prospective health economic
assessment alongside the IN.PACT SFA II (IN.PACT
Admiral Drug-Coated Balloon vs. Standard Balloon
Angioplasty for the Treatment of Superﬁcial Femoral
Artery [SFA] and Proximal Popliteal Artery [PPA])est in PQ Bypass and Vascular Therapies; and is on the boards of VI
ganization) and the Society for Cardiovascular Angiography and In
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METHODS
PATIENT POPULATION. The population for this study
was drawn from IN.PACT SFA II trial (NCT01566461), a
multicenter randomized trial of the IN.PACT Admiral
DCB versus standard PTA in patients undergoing
revascularization for symptomatic femoropopliteal
PAD. Because our goal was to understand the eco-
nomics of DCB in the context of the U.S. health care
system, the economic analysis was restricted to those
patients enrolled at U.S. centers (IN.PACT SFA II trial).
The design and outcomes of the overall IN.PACT SFA
trial have been described previously (8,9). Brieﬂy,
after successful pre-dilation, eligible patients with
severe femoral or proximal popliteal stenoses and
symptoms of claudication or ischemic rest pain
(Rutherford classes II to IV) were randomized in a 2:1
fashion to DCB angioplasty or standard PTA. All
patients underwent clinical follow-up, and duplex
ultrasound was performed on all patients at 30-day,
6-month, 12-month, and 24-month follow-up.
OVERVIEW OF STUDY DESIGN AND DATA COLLECTION.
The economic analysis was conducted from the pers-
pective of the U.S. health care system. We prospecti-
vely collected detailed resource use data for the index
hospitalization and all subsequent hospitalizations
for vascular care; hospital billing data including sum-
mary statements (UB-04 forms) aswell as itemized bills
were also collected. At baseline and at each follow-up
visit through 24 months, quality-of-life assessments
were performed using the EuroQol 5-dimensions
questionnaire (13). All clinical endpoints were adjudi-
cated by a blinded clinical events committee.
DETERMINATION OF MEDICAL CARE COSTS. Medical
care costs for the initial hospitalization and through
2-year follow-up were assessed using a combination
of “bottom-up” and “top-down” methods as des-
cribed previously (14). Given the modest sample size
of the study, it was important to limit the scope of the
economic analysis to focus on those costs that wouldVA Physicians (a 501[c][3] not-for-proﬁt education and
terventions. Dr. Schnieder has received modest roy-
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2345be expected to be inﬂuenced by the treatment strat-
egy. Thus, the primary cost endpoint was total PAD-
related costs for the target limb.
PROCEDURAL COSTS. Detailed resource use data
was recorded for each index procedure, and the cost
of each item was estimated on the basis of the mean
hospital acquisition cost for the item in 2014. The
acquisition cost of the DCB was set at $1,375, reﬂect-
ing the average U.S. sales price at the time of the
analysis. Costs of additional disposable equipment,
overhead, and depreciation for the cardiac catheteri-
zation or vascular laboratory were estimated on the
basis of the average cost per procedure at Saint Luke’s
Mid America Heart Institute in 2014 and adjusted for
actual procedure duration.
OTHER HOSPITAL COSTS. All other hospital costs
were determined using “top-down” accounting
methods as described previously (15). Itemized bills
were obtained for the initial hospitalization and any
subsequent vascular-related hospitalizations during
the follow-up period. Hospital costs were determined
by multiplying itemized hospital charges by the cost
center–speciﬁc cost-to-charge ratio obtained from the
hospital’s Medicare cost report (16). For hospitaliza-
tions without billing data (22.1%), nonprocedural
costs were estimated using a linear regression model
including covariates of intensive care unit length of
stay and overall length of stay (model R2 ¼ 0.38).
Inclusion of additional covariates did not signiﬁ-
cantly improve model ﬁt. For follow-up target limb
vascular hospitalizations that did not include a
revascularization procedure, hospitalization costs
were assigned on the basis of the appropriate Medi-
care severity diagnosis-related group. All costs were
converted to 2014 dollars on the basis of the medical
care component of the Consumer Price Index.
HEALTH UTILITIES AND QUALITY-ADJUSTED
LIFE-YEARS. Quality of life was assessed using the
EuroQol 5-dimensions questionnaire, which was
administered to all patients at baseline and at 1-, 6-, 12-
, and 24-month follow-up. The results of the EuroQol
5-dimensions questionnaire were converted to health
utilities using a U.S.-speciﬁc algorithm (13), and
quality-adjusted life-years (QALYs) were calculated
for each patient as time-weighted averages, assuming
that transitions between health states occurred at the
midpoint of each observation period. Missing utility
data were imputed using multiple imputation.
STATISTICAL ANALYSES. Categorical data are re-
ported as frequencies and were compared using the
Fisher exact test. Continuous data are reported as
mean  SD and were compared using the Student
t tests or the Wilcoxon rank sum test as appropriate.Because cost data were not normally distributed, they
were compared using nonparametric bootstrapping
(1,000 replicates). A p value <0.05 was considered to
indicate statistical signiﬁcance for all comparisons.
COST-EFFECTIVENESS MODEL AND ANALYSES.
The original analytic plan was to perform a patient-
level cost-effectiveness analysis using the observed
2-year cost and QALY data for each patient. However,
as reported previously for the overall IN.PACT SFA
trial population (9), a signiﬁcant imbalance in 2-year
mortality was observed between treatment arms in
the IN.PACT SFA II trial (10.7% for the DCB angio-
plasty group vs. 0% for the standard PTA group,
p ¼ 0.005). However, there were several reasons to
believe that this differential mortality was a chance
ﬁnding. First, the majority of these deaths occurred
late in the second year of the follow-up period.
Second, after adjudication by an independent, blin-
ded clinical events committee, no relationship was
found between any death and either the study device
or index revascularization procedure. Finally, the
observed mortality rate in the standard PTA group
was considerably lower than has been seen in other
contemporary PAD studies (9,17,18), suggesting that
the low mortality rate in the control group was likely
a spurious ﬁnding related to the relatively small
sample size of the standard PTA group.
Because differential mortality would have led to
lower than expected costs as well as QALYs in the DCB
angioplasty group (with an unpredictable effect on the
cost-effectiveness ratios), it was necessary to use a
different analytic approach to compensate for this
unexpected result. Therefore, a state-transition Mar-
kov model was developed to project 2-year costs and
QALYs for the IN.PACT SFA II population. Consistent
with the empirical nature of the analysis, all model
parameters were on the basis of the observed data from
the study population, except that long-term mortality
was assumed to be equal for the 2 treatment groups.
Full details of the model structure and underlying as-
sumptions are provided in the Online Appendix.
COST-EFFECTIVENESS ANALYSES. The primary
cost-effectiveness analysis was performed as a cohort
analysis using the Markov model to estimate 2-year
QALYs and costs for treatment with either DCB an-
gioplasty or standard PTA for a typical patient from
the IN.PACT SFA II trial. The incremental cost-
effectiveness ratio (ICER) was calculated for DCB
angioplasty versus standard balloon PTA as the dif-
ference in 2-year costs divided by the difference in
2-year QALYs. We then performed 1-way sensitivity
analyses on each of the model parameters to identify
which factors had the greatest impact on the ICERs.
TABLE 1 Baseline Patient Characteristics
DCB
(n ¼ 121)
PTA
(n ¼ 60) p Value
Age (yrs) 68.4  8.8 68.2  9.7 0.891
Male (%) 77 (63.6) 38 (63.3) 0.968
Diabetes (%) 58 (47.9) 24 (40.0) 0.313
Current smoking (%) 39 (32.2) 18 (30.0) 0.761
Rutherford class (%) 0.357
II 50 (41.3) 23 (38.3)
III 62 (51.2) 34 (56.7)
IV 9 (7.4) 2 (3.3)
V 0 (0.0) 1 (1.7)
Target lesion length (cm)* 8.5  4.9 9.3  5.6 0.322
Total occlusion (%)* 19.7 16.4 0.591
Reference vessel diameter* (mm) 4.8  0.9 4.7  0.8 0.486
Percentage stenosis (%)* 79  16 80  13 0.541
Values are mean  SD or n (%). *Lesion characteristics analysis: DCB, n ¼ 122; PTA,
n ¼ 61.
DCB ¼ drug-coated balloon; PTA ¼ percutaneous transluminal angioplasty.
TABLE 2 Index Proc
Procedure duration (m
Guidewires
Guiding sheaths/cathet
Diagnostic/Glide cathet
Backup/support cathet
Pre-dilation balloons
IN.PACT Admiral paclit
coated balloons
Post-dilation balloons
Provisional stents
IVUS catheters
Contrast volume (ml)
Closure devices
Device costs ($)
Room/overhead costs (
Medication costs ($)
Nonphysician personne
costs ($)
Additional supply costs
Total procedure costs (
Values are mean  SD.
CI ¼ conﬁdence interval
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2346Finally, to more fully characterize the uncertainty
surrounding our results, we performed a probabilistic
sensitivity analysis in which all model parameters
were sampled from their respective distributions.
A total of 1,000 independent analyses were per-
formed, and the results are reported in terms of a
cost-effectiveness acceptability curve, which de-
scribes the probability that DCB angioplasty will beedure Resource Use and Costs
DCB
(n ¼ 121)
Standard PTA
(n ¼ 60) Difference (95% CI) p Value
in) 156  115 171  121 15 (52 to 21) 0.42
2.3  1.4 2.6  1.4 0.2 (0.7 to 0.2) 0.28
ers 1.8  1.0 2.0  1.1 0.1 (0.4 to 0.2) 0.41
ers 0.8  0.9 1.2  1.0 0.3 (0.6 to 0.1) 0.02
ers 0.2  0.4 0.2  0.4 0.0 (0.1 to 0.1) 0.70
1.1  0.4 1.1  0.3 0.0 (0.1 to 0.2) 0.36
axel- 1.4  0.6 0.0  0.0 1.4 (1.2 to 1.6) <0.001
0.2  0.4 0.2  0.4 0.0 (0.1 to 0.1) 0.91
0.0  0.2 0.2  0.4 0.1 (0.2 to 0.0) 0.003
0.0  0.2 0.1  0.3 0.0 (0.1 to 0.0) 0.46
177  95 192  111 15 (47 to 16) 0.34
0.6  0.5 0.6  0.5 0.0 (0.1 to 0.2) 0.80
3,012  1,079 1,444  807 1,568 (1,257 to 1,879) <0.001
$) 2,276  1,681 2,495  1,759 219 (751 to 312) 0.38
33  154 31  178 2 (49 to 53) 0.86
l 525  280 562  293 37 (125 to 52) 0.38
($) 72  0 72  0 0.0 (0.0 to 0.0) 1.00
$) 5,953  2,426 4,604  2,331 1,349 (601 to 2,097) 0.002
; IVUS ¼ intravascular ultrasound; other abbreviations as in Table 1.economically attractive (i.e., cost effective) at any
societal cost-effectiveness threshold (19).
RESULTS
PATIENT POPULATION. Between April 2012 and
January 2013, a total of 181 U.S. patients were enrolled
in the IN.PACT SFA II trial and randomized to either
initial DCB treatment with the IN.PACT Admiral
balloon (n ¼ 121) or standard PTA (n ¼ 60). Baseline
characteristics were well balanced between the 2
groups with respect to key demographic, clinical, and
angiographic characteristics (Table 1).
INDEX HOSPITALIZATION RESOURCE USE AND
COSTS. Resource use and costs for the index revas-
cularization procedure and the associated hospitali-
zation are summarized in Tables 2 and 3. On average,
1.4  0.6 DCBs were used to treat each patient in the
DCB arm. Provisional stenting was performed more
frequently in patients treated with standard PTA
(13.3% vs. 2.5%; p ¼ 0.007). Index procedural costs
were approximately $1,300 per patient higher for the
DCB angioplasty group compared with standard PTA
($5,953 vs. $4,604; p ¼ 0.002), driven by the cost of
the DCB itself. During the initial hospitalization, there
were no signiﬁcant differences in clinical events or
length of stay; total index hospitalization costs were
$1,129 higher for patients treated with DCB angio-
plasty compared with standard PTA ($8,293 vs.
$7,164; p ¼ 0.03).
2-YEAR OUTCOMES AND COSTS. Clinical outcomes,
resource use, and costs through 2-year follow-up are
summarized in Table 4. Target limb revascularization
procedures were less frequent in patients treated
with DCB angioplasty versus standard PTA (9.9% vs.
30.0%; p < 0.001). When analyzed in terms of the
total number of repeat revascularization procedures,
the difference was slightly larger, reﬂecting the more
frequent need for second and third target limb
revascularization procedures in a small number of
patients in the standard PTA group.
Overall, this reduction in repeat revascularization
procedures was associated with approximately $1,200
per patient lower follow-up target limb–related costs
with DCB angioplasty versus standard PTA; however,
this difference was not statistically signiﬁcant. After
including the cost of the index revascularization
procedures, total target limb–related costs through 2
years were similar in patients treated with DCB an-
gioplasty versus standard PTA ($11,277  $14,224 vs.
$11,359  $8,874; 95% conﬁdence interval for
difference: $4,043 to $3,878; p ¼ 0.95). Mean costs
TABLE 3 Index Hospitalization Resource Use and Costs
DCB
(n ¼ 121)
Standard PTA
(n ¼ 60) Difference (95% CI) p Value
Length of stay (days) 0.65  0.63 0.73  1.21 0.08 (0.35 to 0.19) 0.56
ICU length of stay (days) 0.04  0.30 0.10  0.44 0.06 (0.17 to 0.05) 0.29
Non-ICU length of stay (days) 0.61  0.60 0.63  0.88 0.02 (0.24 to 0.20) 0.85
Nonprocedural hospitalization
costs ($)*
1,774  1,619 1,966  2,041 192 (743 to 360) 0.53
Inpatient physician fees ($) 566  110 594  193 28 (73 to 16) 0.30
Total hospitalization cost ($) 8,293  3,230 7,164  3,325 1,129 (113 to 2,146) 0.03
Values are mean  SD. *Nonprocedural hospitalization costs include the room, nursing, and ancillary costs.
ICU ¼ intensive care unit; other abbreviations as in Tables 1 and 2.
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2347within the DCB angioplasty group were strongly
inﬂuenced by a single high-cost outlier who required
a total of 6 vascular-related hospitalizations and
7 target limb revascularization procedures over the
2-year follow-up period. In an analysis in which that
patient’s follow-up costs were trimmed to those of
the next highest cost patient, mean total 2-year costs
were about $700 per patient lower with DCB angio-
plasty versus standard PTA ($10,656  $8,776 vs.
$11,359  $8,874; p ¼ 0.61).
UTILITY WEIGHTS AND QUALITY-ADJUSTED LIFE
EXPECTANCY. At baseline and 1-month follow-up,
mean utility weights were virtually identical be-
tween the DCB angioplasty and standard PTA groups
(Table 5). Although there were trends toward higher
utilities with DCB at 12- and 24-month follow-up,
none of these differences were statistically signiﬁ-
cant. Quality-adjusted life expectancy over the 2-year
follow-up period was also similar for the DCB angio-
plasty and standard PTA groups (1.53  0.44 vs. 1.47 
0.42; p ¼ 0.40). For patients surviving through 2-year
follow-up, those who required at least 1 repeat
revascularization had numerically fewer 2-year
QALYs than patients who did not require repeat
revascularization (1.47 vs. 1.52; p ¼ 0.59). After
adjusting for age, sex, and 1-month utility, the
reduction in QALYs associated with repeat revascu-
larization (i.e., the disutility of repeat revasculariza-
tion) was 0.059  0.034.
COST-EFFECTIVENESS ANALYSIS. Under our base-
case assumptions, including the assumption of
identical mortality for the 2 groups, the trial-based
Markov model projected that index DCB angioplasty
treatment would be an economically dominant
strategy, with lower 2-year costs (by $576) and a small
gain in QALYs of 0.01. The results of 1-way sensitivity
analyses to examine the impact of variation of key
model inputs on the ICER for DCB angioplasty versus
standard PTA are displayed in Figure 1. The ICER for
DCB versus standard PTA exceeded $50,000 per QALY
gained only if the cost of repeat revascularization
after PTA was <$8,647 (vs. base-case assumption of
$12,772) or if the relative risk for target limb revas-
cularization during the ﬁrst year of follow-up excee-
ded 0.57 (vs. base-case assumption 0.30).
Probabilistic sensitivity analysis demonstrated
moderate uncertainty in these results, mainly because
of considerable variability in the 2-year cost difference
between the 2 treatments (Figure 2). As shown in the
cost-effectiveness acceptability curve (Figure 3), the
probability that the DCB angioplasty strategy was
economically attractive at a societal willingness-to-
pay threshold of $50,000 per QALY gained was69.7%. At a more liberal willingness-to-pay threshold
of $150,000 per QALY gained, the probability that the
DCB strategy was economically attractive was 79.3%.
When we used the full population of the IN.PACT SFA
trial (pooled data from IN.PACT SFA I and IN.PACT SFA
II) to estimate the relative risk for target limb revas-
cularization, the probability that the DCB strategy was
economically attractive at thresholds of $50,000 per
QALY gained and $150,000 per QALY gained was
similar at 65.1% and 75.5%, respectively.
DISCUSSION
This study is the ﬁrst prospective economic analysis
of DCB angioplasty versus standard PTA for treatment
of intermittent claudication secondary to severe
femoropopliteal PAD. On the basis of results obtained
alongside the IN.PACT SFA II trial, we found that the
initial costs of PTA using the DCB were approximately
$1,100 per patient higher than with PTA alone. How-
ever, reductions in the need for repeat target limb
revascularization over 2-year follow-up led to sub-
stantial cost offsets such that total 2-year target
limb–related costs were virtually identical for the 2
strategies. When we performed a formal cost-
effectiveness analysis using a decision-analytic
model that was on the basis of the empirical trial
data (and assuming equal long-term mortality), we
found that the initial DCB angioplasty strategy was
economically dominant, with projected 2-year cost
savings of $576 per patient and a gain in quality-
adjusted life expectancy of 0.01 years. Although
there was uncertainty in these projections (particu-
larly the difference in costs), the overall results were
relatively robust in sensitivity analyses. Speciﬁcally,
in a probabilistic sensitivity analysis in which all
model parameters were varied simultaneously, the
probabilities that the DCB angioplasty strategy would
be cost-effective at thresholds of $50,000 and
$150,000 per QALY gained—thresholds that are
TABLE 4 2-Year Follow-Up Events and Costs
DCB (n ¼ 121) Standard PTA (n ¼ 60) Difference (95% CI) p Value
Clinical events (%)
Death 10.7 0.0 10.7 (5.2 to 16.3) 0.005
Limb-related death 0 0 0 1.00
Target limb revascularization 9.9 30.0 20.1 (32.8 to 7.3) <0.001
PTA 9.9 30.0 20.1 (32.8 to 7.3) <0.001
Surgical bypass 0.8 0 0.8 (0.8 to 2.4) 1.00
Target vessel revascularization 9.1 26.7 17.6 (29.9 to 0.3) 0.002
PTA 9.1 26.7 17.6 (29.9 to 5.3) 0.002
Surgical bypass 0.8 0.0 0.8 (0.8 to 2.4) 1.00
Amputation 1.7 1.7 0 (4.0 to 4.0) 1.00
Resources (count per 100 patients)
Target limb revascularization 20.7  99.9 41.7  78.7 21.0 (50.1 to 8.1) 0.16
PTA 20.7  99.9 41.7  78.7 21.0 (50.1 to 8.1) 0.16
Surgical bypass 1.7  18.2 0.0  0.0 1.7 (3.0 to 6.3) 0.48
Target vessel revascularization 19.8  99.7 38.3  78.3 18.5 (47.5 to 10.5) 0.21
PTA 18.2  83.7 38.3  78.3 20.2 (45.7 to 5.4) 0.12
Surgical bypass 1.7  18.2 0.0  0.0 1.7 (3.0 to 6.3) 0.48
Amputation 1.7  12.8 5.0  38.7 3.4 (11.0 to 4.3) 0.39
Vascular hospitalization for the target limb 19.0  84.0 45.0  96.0 26.0 (53.0 to 2.0) 0.06
Costs ($)
Target limb vascular hospitalizations 2,171  12,208 3,158  7,143 987 (4,354 to 2,379) 0.48
Inpatient physician fees 208  1,029 368  933 159 (470 to 152) 0.30
Follow-up medications 605  757 670  776 65 (303 to 173) 0.54
2-year follow-up 2,984  13,247 4,196  8,251 1,212 (4,899 to 2,476) 0.44
Values are % or mean  SD.
Abbreviations as in Tables 1 and 2.
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2348currently considered to represent high and interme-
diate economic value within the U.S. health care
system (20)—were estimated at 69.7% and 79.3%,
respectively. These ﬁndings suggest that for patients
undergoing femoropopliteal revascularization who
are similar to those enrolled in the IN.PACT SFA II
trial, a strategy of initial DCB angioplasty treatment is
likely to be reasonably cost effective (if not econom-
ically dominant) compared with standard PTA within
the context of the U.S. health care system.
COMPARISON WITH PREVIOUS STUDIES. Several
previous studies have used decision-analyticTABLE 5 Utility Weights by Treatment Group
DCB
(n ¼ 121)
Standard PTA
(n ¼ 60) p Value
Baseline 0.74  0.02 0.75  0.02 0.71
1 month 0.85  0.01 0.85  0.02 0.84
6 months 0.81  0.01 0.82  0.02 0.69
12 months 0.83  0.02 0.78  0.02 0.10
24 months 0.82  0.02 0.77  0.03 0.12
Values are mean  SE.
Abbreviations as in Table 1.modeling to evaluate the cost-effectiveness of alter-
native approaches to percutaneous revascularization
for femoropopliteal PAD. To date, Pietzsch et al. (12)
have performed the only study to examine this issue
from the perspective of the U.S. health care system.
They used a decision-analytic model to estimate the
2-year costs of standard balloon angioplasty, bare-
metal stenting, DCB angioplasty, and drug-eluting
stents from both a payer’s perspective (Medicare) as
well as the perspective of hospitals providing vascular
care. With the exception of 1 trial comparing drug-
eluting stenting versus PTA, clinical outcomes data
for their model were derived predominantly from
small trials examining predominantly mechanistic
endpoints across a heterogeneous patient population.
Costs were on the basis of estimated sales prices for
the various devices and published Medicare reim-
bursement rates. On the basis of these model inputs,
they concluded that from a Medicare perspective, DCB
was the lowest cost strategy, followed by DES, stan-
dard PTA, and ﬁnally bare-metal stent implantation.
Although the results reported by Pietzsch et al. (12)
were robust over a range of sensitivity analyses, the
study was limited by the need to derive key parameter
inputs from small studies including patient
FIGURE 1 1-Way Sensitivity Analysis
Univariate sensitivity analyses presented as a tornado diagram. The x-axis represents the incremental cost-effectiveness ratio (ICER) for drug-coated balloon (DCB)
versus standard balloon percutaneous transluminal angioplasty (PTA). The diagram is stacked in order of decreasing width, whereby variations in inputs near the top have
the greatest impact on the ICER. The dotted red line reﬂects a base case of $54,849. QALY ¼ quality-adjusted life-year; TLR ¼ target lesion revascularization.
FIGURE 2 Incremental Cost-Effectiveness of Drug-Coated Balloon Versus
Standard Percutaneous Transluminal Angioplasty
Scatterplot of the joint distribution of cost and quality-adjusted life-year (QALY)
differences between drug-coated balloon (DCB) angioplasty and standard balloon
percutaneous transluminal angioplasty (PTA) for a population of patients similar to
IN.PACT SFA II (IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty
for the Treatment of Superﬁcial Femoral Artery [SFA] and Proximal Popliteal Artery [PPA])
on the basis of probabilistic sensitivity analysis. Each dot represents a model-based
simulation. The diagonal lines represent willingness-to-pay (WTP) thresholds of $50,000
per QALY gained and $150,000 per QALY gained.
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2349populations that often differed substantially with
respect to key variables such as lesion length. Our
study extends these ﬁndings by using prospectively
collected clinical event rates, resource use, and cost
data obtained alongside an adequately powered ran-
domized clinical trial to inform the decision-analytic
model. In addition, ours is the ﬁrst U.S.-based
analysis to evaluate not only costs but also cost-
effectiveness. The fact that our cost-effectiveness
results were on the basis of prospectively collected
health status data further strengthens our ﬁndings.
Our study reached similar conclusions to those of
Kearns et al. (11), who used a decision-analytic
model to examine the cost-effectiveness of several
alternative approaches to lower extremity revascu-
larization for the treatment of both intermittent
claudication and critical limb ischemia from the
perspective of the United Kingdom National Health
Service. Similar to Pietzsch et al. (12), they relied on
inputs from disparate studies to inform their model.
In a lifetime cost-effectiveness analysis, they found
that PTA with a DCB was a dominant strategy
compared with each of the competing revasculari-
zation strategies, including standard balloon angio-
plasty, drug-eluting stent or bare-metal stent use
(either as a primary approach or a bailout strategy),
stent graft implantation, vascular brachytherapy, or
cryotherapy. On the basis of probabilistic sensitivity
analyses, the probability that DCB angioplasty would
be cost-effective ranged from 58.3% to 63.2% across
FIGURE 3 Probability That Drug-Coated Balloon Angioplasty Is Cost Effective Across Willingness-to-Pay Thresholds
The proportion of incremental cost-effectiveness ratio replicates from probabilistic sensitivity analyses that demonstrate economically
attractive results across a range of willingness-to-pay thresholds. QALY ¼ quality-adjusted life-year.
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QALY to £100,000 per QALY.
Our study provides several important advantages
over these previous studies. First, by prospectively
collecting resource use and cost data alongside a
randomized clinical trial, our study required few as-
sumptions regarding the actual cost of the alternative
revascularization procedures. In contrast, for each
of the previous studies, costs for the various in-
terventions were on the basis of a variety of simpli-
fying assumptions. For example, Pietzsch et al. (12)
assumed that only 1 DCB was used for both index
and repeat revascularization procedures, but we
observed that use of more than 1 device was frequent
among patients treated with DCB (mean 1.4  0.6
DCBs per procedure), a key driver of procedural cost.
Similarly, in the absence of empirical data, Pietzch
et al. (12) assumed that patients would undergo a
maximum of 1 repeat intervention during the 2-year
follow-up interval. In contrast, we noted that many
patients required >1 repeat revascularization pro-
cedure, and we modeled both the cost and quality of
life impact of multiple events explicitly. Finally,
previous studies also assumed similar costs for
follow-up angioplasty regardless of whether the pa-
tient was treated with DCB or standard balloon an-
gioplasty at the index procedure. However, in
IN.PACT SFA II, we found that repeat revasculariza-
tion treatment patterns (and the associated costs)differed substantially following restenosis with stan-
dard PTA or DCB (higher after initial DCB) and
accounted for these differential costs in our decision-
analytic model as well.
STUDY LIMITATIONS. The results of our study should
be considered in light of several limitations. First,
only patients from the United States were included in
the primary economic analysis, and these results may
not be generalizable to patients in other health care
systems that have different patterns of care and cost
structures. Moreover, given the size of the U.S. phase
of the IN.PACT trial, a relatively small number of
patients were included in the analysis, and it is
possible that outliers more strongly inﬂuenced costs
and clinical outcomes compared with a larger study.
Nonetheless, the results of several sensitivity ana-
lyses support the robustness of our ﬁndings.
Second, we did not examine the cost-effectiveness
of other approaches to femoropopliteal angioplasty,
such as primary stenting with bare-metal stents or
drug-eluting stents or the use of atherectomy devices.
In the absence of head-to-head comparative data be-
tween the IN.PACT Admiral DCB and these alternative
approaches, however, such comparisons would be
speculative at best. Further studies are thus needed to
examine the relative costs and cost-effectiveness of
these approaches. The results of this study should also
not be extrapolated to other DCBs that differ from the
PERSPECTIVES
WHAT IS KNOWN? DCBs have been shown to improve
long-term patency and reduce clinically-driven target vessel
revascularization rates compared to standard balloon angio-
plasty alone for severe, symptomatic femoral and popliteal PAD.
However, these devices are more expensive than standard
balloons, and their costs and cost-effectiveness compared
with PTA have not been previously studied in a prospective
economic analysis.
WHAT IS NEW? We found that higher initial costs of DCB
angioplasty were offset by lower follow-up costs secondary to
fewer target limb revascularizations over 2-year follow-up.
Formal cost-effectiveness based upon the IN.PACT SFA II results
demonstrated a high probability that DCB are cost-effective
compared with standard PTA using established wiliness-to-pay
thresholds.
WHAT IS NEXT? Further studies are needed to compare the
costs and cost-effectiveness of DCBs with other contemporary
strategies for femoropopliteal PTA, such primary stenting with
bare metal or drug-eluting stents.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 2 2 , 2 0 1 6 Salisbury et al.
N O V E M B E R 2 8 , 2 0 1 6 : 2 3 4 3 – 5 2 IN.PACT SFA Economic Analysis
2351DCB examined in this study with respect to the balloon
platform, drug dose, excipient, and other factors.
Third, as noted earlier, the IN.PACT SFA trial
demonstrated differential 2-year mortality between
the DCB angioplasty arm and the standard PTA arm
(9). Because the most likely explanation for this
excess mortality was chance, we chose to ignore this
ﬁnding with respect to our cost-effectiveness analysis
and to assume equivalent long-term mortality for the
2 treatment strategies. If long-term mortality were
truly higher with DCB use, however, in light of the
small gain in QALYs associated with avoidance of
repeat revascularization, it is likely that we would
have found standard PTA to be the preferred strategy
on clinical grounds, even in the absence of economic
factors.
Fourth, providers evaluating patients at follow-up
were not blinded to treatment assignment in
IN.PACT SFA, and it is possible that this knowledge
could have inﬂuenced repeat revascularization rates.
Finally, our study used a 2-year time horizon. This
approach offers the advantage of using only directly
observed cost and outcome data but does not account
for potential differences in the longer term outcomes
of DCB versus standard balloon angioplasty. Although
existing data indicate a sustained reduction in repeat
revascularization in patients treated with other DCB
platforms (21), longer term clinical and cost outcomes
with the IN.PACT Admiral DCB are currently unknown.
CONCLUSIONS
In this randomized trial of the IN.PACT Admiral DCB
versus standard PTA for patients with intermittent
claudication due to severe femoropopliteal PAD, we
found that the initial DCB angioplasty strategy was
both less costly and more effective with respect to
repeat revascularization than standard balloon an-
gioplasty over 2 years of follow-up. Assuming that
there is no true difference in long-term mortality
between the 2 strategies, formal cost-effectiveness
analysis on the basis of the IN.PACT SFA II trialresults demonstrates that there is a high probability
that use of the DCB is economically attractive
(ICER <$150,000 per QALY) and a reasonable proba-
bility that DCB angioplasty is highly attractive
(ICER <$50,000 per QALY) for such patients. Further
studies are needed to better understand the cost-
effectiveness of DCB PTA compared with other
contemporary strategies such as primary stenting
with bare-metal or drug-eluting stents or use of
atherectomy devices.
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